Exelixis
EXEL
#1627
Rank
โ‚น887.68 B
Marketcap
โ‚น3,172
Share price
1.79%
Change (1 day)
63.03%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): โ‚น23.20

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น24.26. In 2022 the company made an earnings per share (EPS) of โ‚น48.81 a decrease over its 2021 EPS that were of โ‚น63.36.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)โ‚น23.20-52.47%
2022โ‚น48.81-22.97%
2021โ‚น63.36100%
2020โ‚น31.68-65.09%
2019โ‚น90.77-53.91%
2018โ‚น196.94333.96%
2017โ‚น45.38-260.61%
2016-โ‚น28.26-58.75%
2015-โ‚น68.50-42.45%
2014-โ‚น119.025.3%
2013-โ‚น113.0343.48%
2012-โ‚น78.78-264.29%
2011โ‚น47.95-165.88%
2010-โ‚น72.78-32.54%
2009-โ‚น107.89-17.65%
2008-โ‚น131.0175.86%
2007-โ‚น74.50-25.64%
2006-โ‚น100.188.33%
2005-โ‚น92.48-42.86%
2004-โ‚น161.8430.34%
2003-โ‚น124.16-5.23%
2002-โ‚น131.01-0.65%
2001-โ‚น131.87-51.88%
2000-โ‚น274.01

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
โ‚น299.76 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น272.32 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น155.99 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น339.94 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1,212 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1,206 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น159.27 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น856.28-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น71.93-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA